Wake Forest School of Medicine: Donepezil Does Not Improve Chemotherapy-Related Cognitive Impairment
May 21, 2024
May 21, 2024
WINSTON-SALEM, North Carolina, May 21 (TNSres) -- Wake Forest School of Medicine issued the following news release:
Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.
To test whether a dementia drug could improve cognition in breast cancer survivors, researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil . . .
Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.
To test whether a dementia drug could improve cognition in breast cancer survivors, researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil . . .